Research Article
Impact of Interstitial Pneumonia on the Survival and Risk Factors Analysis of Patients with Hematological Malignancy
Table 5
Clinical and laboratory features of IP group.
| | Measured parameter | IP group | value | | IIP group | nIIP group |
| | Sex (males/females) | 23/12 | 18/8 | 0.989 | | Age (years) | 46.9 (7–87) | 54.6 (14–86) | 0.204 | | Smoker | 7 | 5 | 0.940 | | COPD | 3 | 2 | 0.901 | | Asthma | 1 | 1 | 1.000 | | Time from the treatment of HM to IP (mean, months) | 1.9 (0.1–17.7) | 4.1 (0.1–31.5) | 0.017 | | Episodes of IP | 1.0 ± 0 | 1.2 ± 0.4 | 0.022 | | Hemoglobin (g/dL) | 9.9 ± 1.93 | 10.8 ± 2.47 | 0.177 | | Leukocyte count (/uL) | 9734 ± 11050 | 8756 ± 5809 | 0.258 | | Neutrophils percentage (%) | 64.6 ± 25.16 | 66.3 ± 20.06 | 0.948 | | Lymphocyte percentage (%) | 15.9 ± 12.89 | 17.3 ± 10.78 | 0.366 | | Platelet count (103/uL) | 146.2 ± 122.64 | 173.7 ± 121.95 | 0.347 | | C-reactive protein (mg/dL) | 11.7 ± 7.35 | 5.9 ± 5.67 | 0.002 | | LDH (%) (>250 U/L) | 88.6% | 61.5% | 0.029 | | Use of G-CSF | 17.1% (6/35) | 54.8% (14/26) | 0.020 | | Arterial pO2 (mmHg) | 79.21 ± 12.51 | 82.4 ± 12.10 | 0.507 | | Arterial pCO2 (mmHg) | 34.4 ± 4.06 | 36.0 ± 4.36 | 0.137 | | Stem cell transplantation | 2 | 3 | 0.642 | | Radiotherapy | 2 | 4 | 0.387 |
|
|
IIP: infectious interstitial pneumonia; nIIP: noninfectious interstitial pneumonia; COPD: chronic obstructive pulmonary disease; HM: hematological malignancy; IP: interstitial pneumonias; LDH: lactate dehydrogenase.
|
